Vascular Treatment Articles & Analysis
19 news found
Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. In dermatology, new methods for treating benign epidermal lesions are emerging, alongside the development of drug-free therapies to enhance patient well-being. ...
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary ...
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). ...
It occupies a very important position in the field of skin beauty and is widely used in the treatment of various skin damages, especially those related to photodamage and photoaging. ...
In fact, in spite of the very low temperature reached, -10°C, and kept constant during the 50 minutes of treatment, the vascularization and the tonicity of the tissues of the treated area are preserved, as well as the cellular structures and their functionality. ...
IPL photorejuvenation treatment is currently the most advanced high-tech beauty program, and it is also the safest and most effective beauty program. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. ...
100% clinical success rate: zero complications linked to robot up to 30 days post-procedure >95% technical success rate 84.5% average reduction in physician radiation exposure Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, today presents the results of its R-Evolution ...
ByRobocath
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study. ...
ByRobocath
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. ...
ByRobocath
It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. The company employs a total of 400 people, including 300 in Geneva and 40 in Fribourg. ...
Robocath, a company that designs, develops and commercializes cardiovascular robotic platforms for the treatment of vascular diseases, today announces the successful completion of first five robotic coronary angioplasties in Belgium. ...
ByRobocath
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. ...
ByRobocath
I have long had a passion for the importance of specifically designed and studied technology for peripheral vascular disease treatment,” stated Stacy Enxing Seng. “The Duo Venous Stent system and the VIVID Trial are clearly designed with the improvement of deep venous disease treatment in mind. ...
Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including Global GM. Her duties as an independent member of the Strategic Committee will include supporting the governance of Robocath. She will use her extensive ...
ByRobocath
These permanent materials may cause chronic inflammatory reaction in the treated area as well as restrict vascular access for future treatment. University of Minnesota researchers have developed embolic agents that can be absorbed by the body after the therapeutic treatment has been obtained. ...
The AOD2 was utilized during a variety of vascular surgical cases to ligate and occlude target vessels. AOD performance goals were met and clinical reaction was positive. ...